$2.10
0.94% day before yesterday
Nasdaq, Nov 14, 10:00 pm CET
ISIN
US2683111072
Symbol
EDAP

EDAP TMS SA Sponsored ADR Stock price

$2.10
-0.04 1.87% 1M
-0.06 2.78% 6M
-0.11 4.98% YTD
-0.42 16.67% 1Y
-7.96 79.13% 3Y
-2.30 52.27% 5Y
-3.45 62.16% 10Y
-1.56 42.62% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
-0.02 0.94%

Key metrics

Basic
Market capitalization
$79.3m
Enterprise Value
$68.9m
Net debt
positive
Cash
$18.9m
Shares outstanding
37.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.1 | 1.1
EV/Sales
0.9 | 1.0
EV/FCF
negative
P/B
2.5
Financial Health
Equity Ratio
47.5%
Return on Equity
-46.5%
ROCE
-62.3%
ROIC
-89.2%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$73.3m | $70.1m
EBITDA
- | $-27.5m
EBIT
$-24.8m | $-30.0m
Net Income
$-24.4m | $-30.8m
Free Cash Flow
$-35.2m
Growth (TTM | estimate)
Revenue
1.1% | -6.0%
EBITDA
- | -31.7%
EBIT
-6.7% | -25.8%
Net Income
-6.9% | -39.1%
Free Cash Flow
-11.5%
Margin (TTM | estimate)
Gross
42.5%
EBITDA
- | -39.3%
EBIT
-33.9%
Net
-33.4% | -43.9%
Free Cash Flow
-48.1%
More
EPS
$-0.7
FCF per Share
$-0.9
Short interest
0.1%
Employees
310
Rev per Employee
$240.0k
Show more

Is EDAP TMS SA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

EDAP TMS SA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a EDAP TMS SA Sponsored ADR forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a EDAP TMS SA Sponsored ADR forecast:

Buy
67%
Hold
33%

Financial data from EDAP TMS SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
73 73
1% 1%
100%
- Direct Costs 42 42
2% 2%
58%
31 31
5% 5%
42%
- Selling and Administrative Expenses 46 46
8% 8%
63%
- Research and Development Expense 9.58 9.58
-
13%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -25 -25
7% 7%
-34%
Net Profit -24 -24
7% 7%
-33%

In millions USD.

Don't miss a Thing! We will send you all news about EDAP TMS SA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

EDAP TMS SA Sponsored ADR Stock News

Neutral
Seeking Alpha
10 days ago
EDAP TMS S.A. ( EDAP ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Ryan Rhodes - CEO & Director Ken Mobeck - Chief Financial Officer Conference Call Participants John Fraunces - Lifesci Advisors, LLC Charles Wallace - H.C.
Neutral
GlobeNewsWire
10 days ago
EDAP Reports Third Quarter 2025 Financial Results 49% YoY HIFU Revenue Growth, Driven by Increased Focal One® Sales and U.S. Procedure Volumes 167% YoY Growth in Focal One System Placements 15% YoY Growth in U.S. Focal One HIFU Procedures Company to Host Conference Call and Webcast on November 6 at 8:30 a.m. ET AUSTIN, Texas, November 6, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in r...
Neutral
GlobeNewsWire
12 days ago
EDAP to Present at Jefferies Global Healthcare Conference in London Company to Present and Host 1x1 Investor Meetings on Tuesday, November 18 th , 2025   AUSTIN, Texas, November 4, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and host 1x1 investor meetin...
More EDAP TMS SA Sponsored ADR News

Company Profile

EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses in the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Head office France
CEO Ryan Rhodes
Employees 310
Founded 1979
Website focalone.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today